Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TARDOXIndependent statistical analysis of Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02181075).
- TARGETIndependent statistical analysis of Role of On-site CT-derived FFR in the Management of Suspect CAD Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TARGET-ANHIndependent statistical analysis of Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1: Complete Statistical AnalysisIndependent statistical analysis of Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery: Complete Statistical AnalysisIndependent statistical analysis of Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: Complete Statistical AnalysisIndependent statistical analysis of Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Targeting HIV Retention and Improved Viral Load Through Engagement (‘THRIVE’): Complete Statistical AnalysisIndependent statistical analysis of Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE'): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04481373).
- TARGIT-DMIndependent statistical analysis of Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TARMICIndependent statistical analysis of Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TAS-OX for Refractory Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of TAS-OX for Refractory Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02848079).
- TAS3351Independent statistical analysis of A Study of TAS3351 in NSCLC Patients With EGFRmt: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05765734).
- TASALL – TachoSil® Against Liquor Leak: Complete Statistical AnalysisIndependent statistical analysis of TASALL - TachoSil® Against Liquor Leak: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01355627).
- TASCIndependent statistical analysis of Aortoiliac Stenosis in Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06020534).
- TASCIndependent statistical analysis of Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00524771).
- Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TASKPENIndependent statistical analysis of Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- TASTERIndependent statistical analysis of Ticagrelor Administered as Standard Tablet or Orodispersible Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03822377).
- TASvTVSIndependent statistical analysis of Transabdominal and Transvaginal Sonography in Medical Abortion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03047551).
- TatchSleep as a Tool to Aid in Sleep Apnea Analysis: Complete Statistical AnalysisIndependent statistical analysis of TatchSleep as a Tool to Aid in Sleep Apnea Analysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04419714).
- TAXUS Libertē Post Approval Study: Complete Statistical AnalysisIndependent statistical analysis of TAXUS Libertē Post Approval Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00997503).
- TAXYNERGYIndependent statistical analysis of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with…
- TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients: Complete Statistical AnalysisIndependent statistical analysis of TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00867139).
- TCAPIndependent statistical analysis of Ticagrelor in Severe Community Acquired Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01998399).
- TCM-700CIndependent statistical analysis of The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- TCM-PTSDIndependent statistical analysis of Telephone Case Monitoring (TCM) for Veterans With Post-Traumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID: Complete Statistical AnalysisIndependent statistical analysis of TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TD-0903 for ALI Associated With COVID-19: Complete Statistical AnalysisIndependent statistical analysis of TD-0903 for ALI Associated With COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04402866).
- TdBTSIndependent statistical analysis of Tour de Borobudur Troponin Study on Predictors and Synergistic Role of MDA and Hs-CRP Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TDCS-FOGIndependent statistical analysis of Transcranial Direct Current Stimulation for Freezing of Gait: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02266004).
- TDCSSCHIZIndependent statistical analysis of Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TEACOIndependent statistical analysis of TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00296816).
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TEAMIndependent statistical analysis of A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TEAMIndependent statistical analysis of A Phase III Trial of e-TNS for the Acute Treatment of Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TEAMIndependent statistical analysis of An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with…
- TEAMIndependent statistical analysis of Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- TEAMIndependent statistical analysis of Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane: primary endpoint results, effect estimate with confidence interval,…
- TEAMIndependent statistical analysis of Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Team-Focused Implementation in Child Advocacy Centers: Complete Statistical AnalysisIndependent statistical analysis of Team-Focused Implementation in Child Advocacy Centers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05679154).
- TEAMMATEIndependent statistical analysis of Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TEAMS-BPIndependent statistical analysis of TEAMS-BP (The Enhancement of Social Networks to Augment Management of Stroke-Blood Pressure): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TEARIndependent statistical analysis of Treatment of Early Aggressive Rheumatoid Arthritis (TEAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00259610).
- Tecemotide (L-BLP25) in Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Tecemotide (L-BLP25) in Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01496131).
- TECH-EIndependent statistical analysis of Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Technology Enhanced Family Treatment: Complete Statistical AnalysisIndependent statistical analysis of Technology Enhanced Family Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03913013).
- Technology Interventions to Improve Outcomes After Knee Replacement: Complete Statistical AnalysisIndependent statistical analysis of Technology Interventions to Improve Outcomes After Knee Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04482400).